Quality of Life of Emirati Women with Cervical Cancer Using EORTC QLQ-30 and CX24: A First Look in the UAE
Abstract
:1. Introduction
1.1. Incidence and Prevention of Cervical Cancer
1.2. Impact of Cervical Cancer on Quality of Life
1.3. Gaps in the Research and the Need for the Study
2. Methodology
2.1. Study Design and Sample
2.2. Ethics Approval and Consent to Participate
2.3. Data Collection and Study Instrument
- The first part, adapted from [23] with alterations made to certain items to better align with this study, contained items on both sociodemographic variables and reproductive characteristics. The sociodemographic data included the date of birth, level of education, marital status, employment status, and smoking habits. This part also collected data on QoL, such as the disease stage and the time elapsed since diagnosis.
- The second part included the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), a 30-item questionnaire designed to evaluate the physical, psychological, and social well-being of cancer patients. This questionnaire comprises nine scales: five functional scales, a global QoL scale, and three symptom scales (fatigue, pain, and nausea/vomiting). It also includes five single-item symptom scales (shortness of breath, sleep disturbance, loss of appetite, constipation, and diarrhea), as well as a final item that assesses the perceived financial impact of the disease. The first 28 items are rated on a scale from 1 (not at all) to 4 (very much), reflecting the present moment. For Items 29 (overall general health) and 30 (overall QoL), the responses range from 1 (very poor) to 7 (excellent), reflecting the past week.
- The third part included the CC-specific module (EORTC QLQ-CX24), a validated supplementary questionnaire module designed for CC patients. This module is intended to be used alongside the QLQ-C30 and includes three multi-item scales that assess symptom experience, body image, and sexual/vaginal functioning. Additionally, this module features six single items that assess lymphedema, peripheral neuropathy, menopausal symptoms, sexual worry, sexual activity, and sexual enjoyment.
2.4. Statistical Analysis
- -
- Functional scales/global QoL:
- ○
- Scores ≥ 66.7 indicated good functioning/high QoL.
- ○
- Scores < 33.3 indicated poor functioning/low QoL.
- -
- Symptom scales/items:
- ○
- Scores ≥ 66.7 indicated severe/intense symptoms.
- ○
- Scores < 33.3 indicated mild or minimal symptoms.
3. Results
3.1. Characteristics of the Study Sample
3.2. Quality of Life Scale Scores
3.3. Factors Associated with Quality of Life Scale Scores
3.4. Symptom Items on the QLQ-CX24
3.5. Functional Items on the QLQ-CX 24
3.6. Predictors of Quality of Life
4. Discussion, Implications, and Recommendations
4.1. Practical Implications for Practitioners
4.2. Policy Implications
4.3. Implications for Stakeholders
4.4. Healthcare Policy and System Interventions
4.5. Community and Patient-Centered Strategies
4.6. Addressing Income Disparities in the QoL of Cervical Cancer Survivors
5. Conclusions and Future Directions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
CC | Cervical cancer |
EORTC | European Organization of Research and Treatment for Cancer |
HT | Hormone therapy |
QoL | Quality of life |
QLQ-C30 | Quality of Life Questionnaire—Core 30 |
QLQ-CX24 | Quality of Life Questionnaire—Cervical Cancer Module 24 |
RT | Radiation therapy |
References
- World Health Organization. Cervical Cancer. WHO Fact Sheets. 2022. Available online: https://www.who.int/health-topics/cervical-cancer#tab=tab_1 (accessed on 24 November 2024).
- Viveros-Carreño, D.; Fernandes, A.; Pareja, R. Updates on cervical cancer prevention. Int. J. Gynecol. Cancer 2023, 33, 394–402. [Google Scholar] [CrossRef] [PubMed]
- Vali, M.; Maleki, Z.; Nikbakht, H.-A.; Hassanipour, S.; Kouhi, A.; Nazemi, S.; Hajizade-Valokolaee, M.; Nayeb, M.; Ghaem, H. Survival rate of cervical cancer in Asian countries: A systematic review and meta-analysis. BMC Women’s Health 2023, 23, 671. [Google Scholar] [CrossRef] [PubMed]
- UAE National Cancer Registry. Cancer Incidence in United Arab Emirates Annual Report 2021; Ministry of Health and Prevention: Dubai, United Arab Emirates, 2021. [Google Scholar]
- Al-Shamsi, H.O.; Iqbal, F.; Saad, M.S.A.; Dhemre, P.A.; Hachem, F.G.; Afrit, M.; Abu-Gheida, I.; Tirmazy, S.H.; Dreier, N.W.; Haq, U.U.; et al. The burden of gynecologic cancers in the UAE. J. Oncol. Res. Rev. Rep. 2021, 2, 1–6. [Google Scholar] [CrossRef]
- Elbarazi, I.; Alam, Z.; Abdullahi, A.S.; Al Alawi, S.; AlKhanbashi, M.; Rabaa, A.; Al Aryani, A.; Ahmed, L.; Al-Maskari, F. Knowledge, attitudes and practices of women in the UAE towards breast and cervical cancer prevention: A cross-sectional study. Cancer Control. 2023, 30, 1–10. [Google Scholar] [CrossRef]
- World Health Organization. Cervical Cancer. 2024. Available online: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer (accessed on 7 December 2024).
- Korfage, I.J.; Essink-Bot, M.L.; Mols, F.; van de Poll-Franse, L.; Kruitwagen, R.; van Ballegooijen, M. Health-related quality of life in cervical cancer survivors: A population-based survey. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1501–1509. [Google Scholar] [CrossRef]
- Zhao, M.; Pu, X.; Yan, Y.J.; Zhang, S.; Long, X.; Luo, L.; Li, Z. The quality of life in women with cervical cancer and precancerous lesions of Han and ethnic minorities in Southwest China. BMC Cancer 2021, 21, 1110. [Google Scholar] [CrossRef] [PubMed]
- Prasongvej, P.; Nanthakomon, T.; Jaisin, K.; Chanthasenanont, A.; Lertvutivivat, S.; Tanprasertkul, C.; Bhamarapravatana, K.K.; Suwannarurk, K. Quality of life in cervical cancer survivors and healthy women: Thai urban population study. Asian Pac. J. Cancer Prev. 2017, 18, 385–389. [Google Scholar] [CrossRef]
- Basen-Engquist, K.; Scruggs, S.; Jhingran, A.; Bodurka, D.C.; Lu, K.; Ramondetta, L.; Hughes, D.; Taylor, C.C. Physical activity and obesity in endometrial cancer survivors: Associations with pain, fatigue, and physical functioning. Am. J. Obstet. Gynecol. 2009, 200, 288.e1–288.e8. [Google Scholar] [CrossRef]
- Pasek, M.; Goździalska, A.; Jochymek, M.; Caruso, R. Social support in a cancer patient-informal caregiver dyad: A scoping review. Cancers 2023, 15, 1754. [Google Scholar] [CrossRef]
- Alkhalawi, E.; Al-Madouj, A.; Al-Zahrani, A. Cervical cancer incidence and trends among nationals of the Gulf Cooperation Council States, 1998–2012. Gulf J. Oncolog. 2019, 1, 7–13. [Google Scholar]
- Mohamed, M.L.; Tawfik, A.M.; Mohammed, G.F.; Elotla, S.F. Knowledge, attitude, and practice of cervical cancer screening, and HPV vaccination: A cross-sectional study among obstetricians and gynecologists in Egypt. Matern. Child. Health J. 2022, 26, 565–574. [Google Scholar] [CrossRef] [PubMed]
- Ampofo, A.G.; Boyes, A.W.; Khumalo, P.G.; Mackenzie, L. Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education. Gynecol. Oncol. 2022, 164, 675–690. [Google Scholar] [CrossRef]
- Frumovitz, M.; Sun, C.C.; Schover, L.R.; Munsell, M.F.; Jhingran, A.; Wharton, J.T.; Eifel, P.; Bevers, T.B.; Levenback, C.F.; Gershenson, D.M.; et al. Quality of life and sexual functioning in cervical cancer survivors. J. Clin. Oncol. 2005, 23, 7428–7436. [Google Scholar] [CrossRef] [PubMed]
- Maruyama, Y.; Sukegawa, A.; Yoshida, H.; Iwaizumi, Y.; Nakagawa, S.; Kino, T.; Suzuki, Y.; Kubota, K.; Hirabuki, T.; Mizushima, T.; et al. Role of cervical cancer screening during prenatal checkups for infectious diseases: A retrospective, descriptive study. J. Int. Med. Res. 2022, 50, 1–12. [Google Scholar] [CrossRef]
- Membrilla-Beltran, L.; Cardona, D.; Camara-Roca, L.; Aparicio-Mota, A.; Roman, P.; Rueda-Ruzafa, L. Impact of cervical cancer on quality of life and sexuality in female survivors. Int. J. Environ. Res. Public Health 2023, 20, 3751. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Zhao, X.; Cui, M.; Wang, Y. Dimensions of spiritual well-being in relation to physical and psychological symptoms: A cross-sectional study of advanced cancer patients admitted to a palliative care unit. BMC Palliat. Care 2023, 22, 137. [Google Scholar] [CrossRef]
- Palagudi, M.; Para, S.; Golla, N.; Meduri, K.C.; Duvvuri, S.P.; Vityala, Y.; Sajja, D.C.; Damineni, U. Adverse effects of cancer treatment in patients with cervical cancer. Cureus 2024, 16, e54106. [Google Scholar] [CrossRef] [PubMed]
- Khalil, J.; Bellefqih, S.; Sahli, N.; Afif, M.; Elkacemi, H.; Elmajjaoui, S.; Kebdani, T.; Benjaafar, N. Impact of cervical cancer on quality of life: Beyond the short term (results from a single institution): Quality of life in long-term cervical cancer survivors: Results from a single institution. Gynecol. Oncol. Res. Pract. 2015, 2, 7. [Google Scholar] [CrossRef]
- Spagnoletti, B.R.M.; Bennett, L.R.; Keenan, C.; Shetty, S.S.; Manderson, L.; McPake, B.; Wilopo, S.A. What factors shape quality of life for women affected by gynecological cancer in South, Southeast and East Asian countries? A critical review. Reprod. Health 2022, 19, 70. [Google Scholar] [CrossRef]
- Smail, L.; Jassim, G.; Khan, S.; Tirmazy, S.; Ameri, M.A. Quality of life of Emirati women with breast cancer. Int. J. Environ. Res. Public Health 2022, 20, 570. [Google Scholar] [CrossRef]
- Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; Haes, J.C.J.M.D.; et al. The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85, 365–376. [Google Scholar] [CrossRef] [PubMed]
- Fayers, P.M.; Aaronson, N.K.; Bjordal, K.; Groenvold, M.; Curran, D.; Bottomley, A. The EORTC QLQ-C30 Scoring Manual; European Organization for Research and Treatment of Cancer: Brussels, Belgium, 2001. [Google Scholar]
- Greimel, E.R.; Vlasic, K.K.; Waldenstrom, A.C.; Duric, V.M.; Jensen, P.T.; Singer, S.; Chie, W.; Nordin, A.; Bjelic Radisic, V.; Wydra, D. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module. Cancer 2006, 107, 1812–1822. [Google Scholar] [CrossRef] [PubMed]
- Yoo, S.H.; Yun, Y.H.; Park, S.; Kim, Y.A.; Park, S.Y.; Bae, D.S.; Nam, J.H.; Park, C.T.; Cho, C.H.; Lee, J.M. The correlates of unemployment and its association with quality of life in cervical cancer survivors. J. Gynecol. Oncol. 2013, 24, 367–375. [Google Scholar] [CrossRef]
- Luísa, S.; Abreu, D.S. Cervical cancer and quality of life: Systematic review. Clin. J. Obstet. Gynecol. 2024, 7, 17–24. [Google Scholar] [CrossRef]
- Kajimoto, Y.; Honda, K.; Suzuki, S.; Mori, M.; Tsubouchi, H.; Nakao, K.; Azuma, A.; Shibutani, T.; Nagao, S.; Koyanagi, T.; et al. Association between financial toxicity and health-related quality of life of patients with gynecologic cancer. Int. J. Clin. Oncol. 2023, 28, 454–467. [Google Scholar] [CrossRef]
- Jafari, A.; Hosseini, F.A.; Jalali, F.S. A systematic review of the economic burden of colorectal cancer. Health Sci. Rep. 2024, 7, e70002. [Google Scholar] [CrossRef] [PubMed]
- Barnaś, E.; Skręt-Magierło, J.; Skręt, A.; Bidziński, M. The quality of life of women treated for cervical cancer. Eur. J. Oncol. Nurs. 2012, 16, 59–63. [Google Scholar] [CrossRef]
- Shylasree, T.S.; Ranade, R.; Kattepur, A.; Kaur, S.; Dusane, R.; Maheshwari, A.; Mahantshetty, U.; Chopra, S.; Engineer, R.; Kerkar, R. Quality of life in long term survivors of cervical cancer: A cross sectional study. Indian J. Cancer 2021, 58, 171–178. [Google Scholar] [CrossRef]
Variable | Cervical Cancer Survivors, n (%) |
---|---|
Age (years), mean | 43.1 ± 11.4 |
24–34 | 15 (20.8) |
35–44 | 31 (43.1) |
45–54 | 12 (16.7) |
54–72 | 14 (19.4) |
Education level | |
Illiterate | 3 (4.2) |
Primary and preparatory school | 12 (16.7) |
Secondary school | 18 (25) |
University undergraduate | 29 (40.3) |
University postgraduate | 10 (13.9) |
Marital status | |
Single | 10 (13.9) |
Married | 55 (76.4) |
Divorced | 7 (9.7) |
Employment status | |
Employed | 41 (56.9) |
Not employed (1 retired) | 31 (43.1) |
Smoking habits | |
Smoker | 13 (18) |
Nonsmoker | 55 (76.4) |
Previous smoker | 4 (5.6) |
Family income (AED) | |
≤10,000 (USD 2500) | 44 (61.1) |
10,000–20,000 (USD 2500–5000) | 10 (13.9) |
20,000–30,000 (USD 5000–7500) | 9 (12.5) |
≥30,000 (>USD 7500) | 9 (12.5) |
Exercise status | |
Yes | 35 (48.6) |
Contraception use | |
Yes | 33 (45.8) |
No | 39 (54.2) |
Contraceptive used | |
Hormonal contraceptive pills | 10 (30.3) |
Condoms | 13 (39.4) |
Intrauterine device | 10 (30.3) |
Family history of cancer/CC | |
Yes | 19 (26.4) |
No | 44 (61.1) |
Don’t know | 9 (12.5) |
Time since diagnosis (years), mean | 1.9 ± 2.9 |
<1 | 19 (26.4) |
1–2 | 35 (48.6) |
2–3 | 9 (12.5) |
3–4 | 3 (4.2) |
4–5 | 3 (4.2) |
>5 | 3 (4.2) |
Cancer stage | |
0 | 9 (12.5) |
I | 22 (30.6) |
II | 15 (20.8) |
III | 13 (18.1) |
IV | 5 (6.9) |
Don’t know | 8 (11.1) |
Age at diagnosis (years), mean | 41.5 ± 11.1 (Range 23–72) |
≤29 | 7 (9.7) |
30–39 | 31 (43.1) |
40–49 | 21 (29.2) |
50–59 | 7 (9.7) |
≥60 | 6 (8.3) |
Treatment method | |
Radiotherapy (RT) | 8 (11.1) |
Chemotherapy (including tablets) | 30 (41.7) |
Surgery | 6 (8.3) |
Hormonal therapy (HT) | 2 (2.8) |
Chemotherapy, HT | 1 (1.4) |
Chemotherapy, RT | 9 (12.5) |
Chemotherapy, RT, HT | 1 (1.4) |
Chemotherapy, RT, surgery | 7 (9.7) |
Does not know | 8 (11.1) |
Surgery type | |
Total hysterectomy | 14 (19.4) |
Radical hysterectomy | 4 (5.6) |
Trachelectomy | 3 (4.2) |
Pelvic exenteration | 7 (9.7) |
Partial hysterectomy, excluding the cervix | 5 (6.9) |
Other a | 17 (23.6) |
Metastasis to other parts of the body | |
Yes | 22 (30.6) |
No | 40 (55.6) |
Don’t know | 10 (13.9) |
Variables | Items, n | Mean ± SD | 95% CI | Score, n (%) | |
---|---|---|---|---|---|
<33.3 a | ≥66.7 b | ||||
QLQ-C30 | |||||
Global health status/QoL | 2 | 64.4 ± 20.4 | 59.6–69.2 | 1 (1.4) | 26 (36.1) |
Functional scales b | |||||
Physical functioning | 5 | 64.3 ± 21.9 | 59.1–69.4 | 6 (8.3) | 32 (44.4) |
Role functioning | 2 | 65.1 ± 25.0 | 59.2–70.9 | 4 (5.6) | 22 (30.6) |
Emotional functioning | 4 | 65.2 ± 23.8 | 59.6–70.8 | 6 (8.3) | 29 (40.3) |
Cognitive functioning | 2 | 69.9 ± 23.5 | 64.4–75.4 | 2 (2.8) | 32 (44.4) |
Social functioning | 2 | 61.8 ± 25.2 | 55.9–67.7 | 3 (4.2) | 17 (23.6) |
Symptom scales c | |||||
Fatigue | 3 | 41.5 ± 27.5 | 35.0–48.0 | 26 (36.1) | 9 (12.5) |
Nausea and vomiting | 2 | 26.6 ± 26.8 | 20.3–32.9 | 35 (48.6) | 3 (4.2) |
Pain | 2 | 39.4 ± 27.6 | 32.9–45.8 | 19 (26.4) | 9 (12.5) |
Dyspnea | 1 | 25.5 ± 28.8 | 18.7–32.2 | 34 (47.2) | 3 (4.2) |
Sleep disturbance—insomnia | 1 | 40.7 ± 31.3 | 33.4–48.1 | 17 (23.6) | 8 (11.1) |
Appetite loss | 1 | 30.6 ± 32.5 | 22.9–38.2 | 30 (41.7) | 7 (9.7) |
Constipation | 1 | 36.1 ± 34.8 | 27.9–44.3 | 26 (36.1) | 10 (13.9) |
Diarrhea | 1 | 22.2 ± 31.1 | 14.9–29.5 | 41 (56.9) | 6 (8.3) |
Financial impact | 1 | 38.4 ± 34.8 | 30.3–46.6 | 22 (30.6) | 12 (16.7) |
QLQ-CX24 | |||||
Symptom scales c | |||||
Symptom experience | 11 | 29.6 ± 17.3 | 25.5–33.7 | 34 (47.2) | 1 (1.4) |
Body image | 3 | 39.2 ± 31.3 | 31.9–46.5 | 25 (34.7) | 10 (13.9) |
Sexual/vaginal functioning (n = 44) | 4 | 29.5 ± 27.8 | 21.1–38.0 | 25 (34.7) | 5 (6.9) |
Lymphedema | 1 | 25.5 ± 32.4 | 17.9–33.1 | 39 (54.2) | 5 (6.9) |
Peripheral neuropathy | 1 | 29.6 ± 30.4 | 22.5–36.8 | 29 (40.3) | 5 (6.9) |
Menopausal symptoms | 1 | 33.3 ± 28.0 | 26.8–39.9 | 20 (27.8) | 5 (6.9) |
Sexual worry | 1 | 31.9 ± 32.8 | 24.2–39.7 | 29 (40.3) | 7 (9.7) |
Functional scales b | |||||
Sexual activity | 1 | 26.9 ± 27.2 | 20.5–33.2 | 31 (43.1) | 1 (1.4) |
Sexual enjoyment (n = 47) | 1 | 27.7 ± 30.5 | 18.7–36.6 | 22 (30.6) | 2 (2.8) |
Characteristics | Global Health Status/Qol b | Physical Functioning b | Role Functioning b | Emotional Functioning b | Cognitive Functioning b | Social Functioning b |
---|---|---|---|---|---|---|
Age (years), mean ± SD | ||||||
24–34 | 63.3 ± 19.9 | 58.7 ± 16.8 | 64.4 ± 21.7 | 61.1 ± 21.5 | 70.0 ± 23.7 | 64.4 ± 28.8 |
35–44 | 65.1 ± 17.0 | 69.5 ± 18.4 | 67.7 ± 20.2 | 72.3 ± 19.6 | 74.7 ± 21.0 | 65.1 ± 21.2 |
45–54 | 68.1 ± 20.0 | 67.8 ± 18.2 | 62.5 ± 31.1 | 61.8 ± 28.7 | 58.3 ± 20.7 | 54.2 ± 26.7 |
54–72 | 60.7 ± 28.6 | 55.7 ± 32.6 | 61.9 ± 33.6 | 56.5 ± 28.0 | 69.0 ± 29.1 | 58.3 ± 29.1 |
p-value | 0.869 | 0.319 | 0.922 | 0.231 | 0.192 | 0.574 |
Time since diagnosis (years), mean ± SD | ||||||
<1 | 60.5 ± 15.7 | 62.1 ± 21.3 | 60.5 ± 23 | 66.7 ± 21.7 | 71.1 ± 16.5 | 58.8 ± 26.3 |
1–2 | 60.2 ± 20.4 | 68 ± 18.8 | 69.5 ± 18.3 | 63.3 ± 24.9 | 69.0 ± 24.3 | 66.7 ± 21.8 |
2–3 | 68.5 ± 22.0 | 58.5 ± 31.1 | 66.7 ± 40.8 | 66.7 ± 28.6 | 77.8 ± 23.6 | 51.9 ± 33.8 |
3–4 | 80.6 ± 17.3 | 66.7 ± 29.1 | 55.6 ± 38.5 | 63.9 ± 33.7 | 50 ± 44.1 | 44.4 ± 19.2 |
4–5 | 52.8 ± 45.9 | 60.0 ± 17.6 | 50.0 ± 44.1 | 77.8 ± 17.3 | 72.2 ± 34.7 | 72.2 ± 34.7 |
>5 | 61.1 ± 19.2 | 53.3 ± 35.3 | 61.1 ± 25.5 | 61.1 ± 17.3 | 66.7 ± 28.9 | 61.1 ± 25.5 |
p-value | 0.639 | 0.861 | 0.677 | 0.926 | 0.803 | 0.441 |
Marital status, mean ± SD | ||||||
Single | 59.2 ± 17.3 | 62.0 ± 17.8 | 68.3 ± 18.3 | 53.3 ± 27 | 65.0 ± 28.8 | 51.7 ± 29.9 |
Married | 65.5 ± 18.7 | 64.2 ± 22.9 | 65.8 ± 25.3 | 68.2 ± 21.9 | 72.1 ± 21.8 | 62.7 ± 24.8 |
Divorced | 63.1 ± 35.6 | 67.6 ± 20.9 | 54.8 ± 31.5 | 58.3 ± 30.4 | 59.5 ± 28.6 | 69.0 ± 20.2 |
p-value | 0.606 | 0.834 | 0.551 | 0.192 | 0.400 | 0.386 |
Education level, mean ± SD | ||||||
Illiterate | 50.0 ± 16.7 | 57.8 ± 27.8 | 44.4 ± 41.9 | 55.6 ± 34.7 | 66.7 ± 16.7 | 55.6 ± 48.1 |
Primary and preparatory school | 56.9 ± 26.8 | 62.2 ± 26.7 | 54.2 ± 30.3 | 56.3 ± 27.1 | 58.3 ± 27.1 | 52.8 ± 25.5 |
Secondary school | 65.3 ± 20.1 | 63.3 ± 18.5 | 72.2 ± 21.4 | 66.7 ± 20.6 | 73.1 ± 23 | 63 ± 23.3 |
University undergraduate | 67.2 ± 18.5 | 68.3 ± 17.4 | 70.1 ± 18.6 | 65.5 ± 21.6 | 73.6 ± 20.2 | 64.9 ± 21.5 |
University graduate | 67.5 ± 18.6 | 58.7 ± 32.2 | 56.7 ± 30.6 | 75 ± 28.6 | 68.3 ± 29.9 | 63.3 ± 33.1 |
p-value | 0.511 | 0.859 | 0.373 | 0.400 | 0.491 | 0.526 |
Employment, mean ± SD | ||||||
Yes | 66.7 ± 18.3 | 65.7 ± 21.3 | 69.5 ± 22.9 | 67.3 ± 23.6 | 75.2 ± 21.4 | 66.7 ± 23 |
No | 61.3 ± 22.9 | 62.4 ± 22.8 | 59.1 ± 26.8 | 62.4 ± 24.2 | 62.9 ± 24.6 | 55.4 ± 27 |
p-value | 0.310 | 0.563 | 0.112 | 0.344 | 0.028 | 0.046 |
Monthly income (AED), mean ± SD | ||||||
<10,000 | 58.5 ± 19.3 | 63.9 ± 22.6 | 59.5 ± 26.8 | 61.0 ± 22.3 | 66.7 ± 23.8 | 58.3 ± 27.5 |
10,000–20,000 | 68.3 ± 17.9 | 62 ± 19.9 | 68.3 ± 21.4 | 72.5 ± 22.6 | 78.3 ± 15.8 | 66.7 ± 15.7 |
20,000–30,000 | 65.7 ± 19.7 | 56.3 ± 22.6 | 72.2 ± 20.4 | 66.7 ± 22.8 | 66.7 ± 23.6 | 57.4 ± 25.2 |
>30,000 | 87 ± 12.6 | 76.3 ± 17.7 | 81.5 ± 15.5 | 75.9 ± 31.3 | 79.6 ± 27.4 | 77.8 ± 16.7 |
p-value | 0.002 | 0.271 | 0.079 | 0.089 | 0.197 | 0.192 |
Physical activity, mean ± SD | ||||||
Yes | 68.3 ± 19.5 | 69.7 ± 18 | 71.4 ± 17.9 | 71.7 ± 22.1 | 77.1 ± 22.2 | 69 ± 19 |
No | 60.6 ± 20.8 | 59.1 ± 24.1 | 59 ± 29.3 | 59 ± 24.1 | 63.1 ± 23 | 55 ± 28.6 |
p-value | 0.162 | 0.101 | 0.061 | 0.007 | 0.007 | 0.026 |
Smoking habits, mean ± SD | ||||||
Smoker | 55.8 ± 12.4 | 63.1 ± 17.3 | 59 ± 25.1 | 73.7 ± 16.6 | 66.7 ± 19.2 | 64.1 ± 20.2 |
Nonsmoker | 65.2 ± 21.5 | 64.4 ± 23.7 | 66.7 ± 25.9 | 63.2 ± 25.6 | 70.9 ± 25.1 | 60.9 ± 26.5 |
Previous smoker | 81.3 ± 14.2 | 66.7 ± 5.4 | 62.5 ± 8.3 | 64.6 ± 10.5 | 66.7 ± 13.6 | 66.7 ± 27.2 |
p-value | 0.052 | 0.830 | 0.462 | 0.386 | 0.740 | 0.921 |
Children, mean ± SD | ||||||
Yes | 65.8 ± 21.2 | 65.9 ± 22.4 | 65.5 ± 26.3 | 66.5 ± 24.3 | 70.4 ± 23.6 | 62.6 ± 24.6 |
No | 58.3 ± 16.3 | 57.6 ± 18.8 | 63.1 ± 19.8 | 59.5 ± 21.6 | 67.9 ± 24 | 58.3 ± 28.3 |
p-value | 0.166 | 0.095 | 0.529 | 0.292 | 0.652 | 0.605 |
Stage, mean ± SD | ||||||
0 | 57.4 ± 20.2 | 59.3 ± 22 | 53.7 ± 29.8 | 63.0 ± 30.9 | 61.1 ± 16.7 | 44.4 ± 33.3 |
I | 66.7 ± 18 | 65.5 ± 20.7 | 70.5 ± 23 | 65.5 ± 18.1 | 68.9 ± 24.3 | 61.4 ± 19.5 |
II | 57.8 ± 22.8 | 68.4 ± 17.5 | 68.9 ± 23.5 | 71.1 ± 19.1 | 80 ± 20.1 | 65.6 ± 21.3 |
III | 69.9 ± 19.1 | 61.5 ± 20.9 | 57.7 ± 20 | 65.4 ± 26.1 | 61.5 ± 24.9 | 71.8 ± 21.9 |
IV | 71.7 ± 13.9 | 54.7 ± 34.4 | 40 ± 25.3 | 41.7 ± 20.4 | 53.3 ± 21.7 | 40.0 ± 27.9 |
p-value | 0.313 | 0.812 | 0.063 | 0.214 | 0.087 | 0.047 |
Radiotherapy, mean ± SD | ||||||
Yes | 69 ± 27.3 | 70.7 ± 25.8 | 72 ± 31.1 | 67.7 ± 28.7 | 74.7 ± 24.1 | 67.3 ± 29.5 |
No | 61.9 ± 15.4 | 60.9 ± 18.9 | 61.3 ± 20.6 | 63.8 ± 21 | 67.4 ± 23 | 58.9 ± 22.5 |
p-value | 0.0115 | 0.008 | 0.021 | 0.381 | 0.192 | 0.118 |
Chemotherapy, mean ± SD | ||||||
Yes | 65.8 ± 18.1 | 66.7 ± 22.2 | 66.3 ± 25.9 | 68.4 ± 23.2 | 74.5 ± 22.2 | 64.2 ± 24.6 |
No | 61.7 ± 24.4 | 59.7 ± 20.9 | 62.7 ± 23.7 | 59 ± 24.3 | 61.3 ± 23.9 | 57.3 ± 26.4 |
p-value | 0.434 | 0.122 | 0.487 | 0.090 | 0.023 | 0.252 |
Metastasis, mean ± SD | ||||||
Yes | 62.1 ± 23.2 | 50 ± 21.6 | 53.8 ± 28.6 | 56.4 ± 27.3 | 61.4 ± 24.3 | 51.5 ± 25.1 |
No | 65.4 ± 18.2 | 73.7 ± 16.9 | 71.7 ± 22.4 | 71.7 ± 19.3 | 76.3 ± 21.6 | 68.3 ± 21.6 |
p-value | 0.882 | <0.001 | 0.016 | 0.076 | 0.029 | 0.022 |
Characteristic | Fatigue b | Nausea and Vomiting b | Pain b | Dyspnea b | Insomnia b | Appetite Loss b | Constipation b | Diarrhea b | Financial Difficulties b |
Age (years), mean ± SD | |||||||||
24–34 | 47.4 ± 22.8 | 31.1 ± 28.1 | 42.2 ± 21.7 | 31.1 ± 32 | 42.2 ± 29.5 | 31.1 ± 26.6 | 35.6 ± 32 | 26.7 ± 33.8 | 28.9 ± 27.8 |
35–44 | 32.6 ± 25.2 | 15.6 ± 20.2 | 33.3 ± 24 | 22.6 ± 31.5 | 33.3 ± 28.5 | 16.1 ± 24.1 | 28 ± 29.9 | 17.2 ± 29.7 | 35.5 ± 35.4 |
45–54 | 42.6 ± 29.1 | 31.9 ± 24.1 | 38.9 ± 32.8 | 27.8 ± 23.9 | 30.6 ± 17.2 | 47.2 ± 38.8 | 38.9 ± 37.2 | 13.9 ± 17.2 | 50 ± 36.2 |
54–72 | 54 ± 31.7 | 41.7 ± 32.5 | 50 ± 34.6 | 23.8 ± 24.2 | 64.3 ± 38 | 47.6 ± 36.3 | 52.4 ± 42.8 | 35.7 ± 38 | 45.2 ± 38.4 |
p value | 0.054 | 0.021 | 0.299 | 0.686 | 0.027 | 0.005 | 0.303 | 0.231 | 0.387 |
Time since diagnosis (years), mean ± SD | |||||||||
<1 | 43.9 ± 24.1 | 28.9 ± 23.5 | 41.2 ± 21.1 | 45.6 ± 29.8 | 43.9 ± 27.3 | 31.6 ± 23.5 | 36.8 ± 29.2 | 24.6 ± 29.1 | 45.6 ± 29.8 |
1–2 | 41.9 ± 27.1 | 26.2 ± 27.2 | 36.7 ± 27.9 | 16.2 ± 22 | 41.9 ± 29.5 | 29.5 ± 35 | 37.1 ± 38.6 | 21 ± 33.4 | 31.4 ± 35.2 |
2–3 | 37 ± 33.3 | 13 ± 20 | 40.7 ± 34.5 | 11.1 ± 16.7 | 29.6 ± 42.3 | 18.5 ± 33.8 | 18.5 ± 24.2 | 14.8 ± 33.8 | 48.1 ± 41.2 |
3–4 | 25.9 ± 35.7 | 33.3 ± 33.3 | 50 ± 44.1 | 55.6 ± 50.9 | 44.4 ± 38.5 | 33.3 ± 33.3 | 33.3 ± 33.3 | 44.4 ± 38.5 | 33.3 ± 33.3 |
4–5 | 44.4 ± 50.9 | 44.4 ± 50.9 | 44.4 ± 50.9 | 11.1 ± 19.2 | 44.4 ± 50.9 | 44.4 ± 50.9 | 44.4 ± 50.9 | 22.2 ± 19.2 | 33.3 ± 57.7 |
>5 | 48.1 ± 17 | 33.3 ± 33.3 | 38.9 ± 9.6 | 33.3 ± 33.3 | 33.3 ± 33.3 | 55.6 ± 38.5 | 66.7 ± 33.3 | 22.2 ± 19.2 | 55.6 ± 19.2 |
p value | 0.738 | 0.602 | 0.887 | 0.005 | 0.774 | 0.466 | 0.443 | 0.576 | 0.358 |
Marital status, mean ± SD | |||||||||
Single | 48.9 ± 23 | 20 ± 24.6 | 45 ± 26.1 | 13.3 ± 23.3 | 36.7 ± 29.2 | 33.3 ± 31.4 | 43.3 ± 31.6 | 20 ± 28.1 | 43.3 ± 35.3 |
Married | 39.2 ± 26.9 | 25.2 ± 23.3 | 37.9 ± 26.3 | 29.7 ± 29.9 | 39.4 ± 30.8 | 29.1 ± 31.5 | 33.3 ± 33.3 | 21.2 ± 29.7 | 38.2 ± 33.6 |
Divorced | 49.2 ± 38.4 | 47.6 ± 45.6 | 42.9 ± 40.7 | 9.5 ± 16.3 | 57.1 ± 37.1 | 38.1 ± 44.8 | 47.6 ± 50.4 | 33.3 ± 47.1 | 33.3 ± 47.1 |
p value | 0.407 | 0.375 | 0.588 | 0.068 | 0.392 | 0.852 | 0.540 | 0.917 | 0.661 |
Education level, mean ± SD | |||||||||
Illiterate | 70.4 ± 28 | 33.3 ± 33.3 | 50 ± 50 | 33.3 ± 33.3 | 22.2 ± 19.2 | 44.4 ± 50.9 | 66.7 ± 33.3 | 11.1 ± 19.2 | 55.6 ± 50.9 |
Primary and preparatory school | 57.4 ± 35.7 | 50 ± 29.3 | 52.8 ± 32.4 | 25 ± 25.1 | 63.9 ± 41.3 | 66.7 ± 34.8 | 55.6 ± 47.8 | 36.1 ± 41.3 | 50 ± 36.2 |
Secondary school | 39.5 ± 22 | 18.5 ± 21.3 | 34.3 ± 22.5 | 22.2 ± 25.6 | 40.7 ± 24.4 | 25.9 ± 29.3 | 25.9 ± 24.4 | 20.4 ± 28.3 | 38.9 ± 30.8 |
University undergraduate | 38.7 ± 23.7 | 20.7 ± 24.3 | 37.9 ± 23.5 | 23 ± 29.7 | 32.2 ± 27.4 | 20.7 ± 22.6 | 32.2 ± 31.5 | 17.2 ± 29 | 29.9 ± 33.7 |
University graduate | 25.6 ± 25.7 | 28.3 ± 26.1 | 33.3 ± 33.3 | 36.7 ± 36.7 | 43.3 ± 31.6 | 20 ± 28.1 | 33.3 ± 35.1 | 26.7 ± 30.6 | 43.3 ± 38.7 |
p value | 0.050 | 0.025 | 0.336 | 0.750 | 0.117 | 0.004 | 0.227 | 0.540 | 0.374 |
Employment, mean ± SD | |||||||||
Yes | 38.5 ± 25.7 | 19.5 ± 24.7 | 36.2 ± 24.7 | 21.1 ± 28.6 | 34.1 ± 28.4 | 19.5 ± 25.8 | 30.9 ± 32 | 16.3 ± 29.9 | 30.9 ± 34.5 |
No | 45.5 ± 29.7 | 36 ± 26.9 | 43.5 ± 30.9 | 31.2 ± 28.5 | 49.5 ± 33.2 | 45.2 ± 35 | 43 ± 37.7 | 30.1 ± 31.5 | 48.4 ± 33.2 |
p value | 0.351 | 0.007 | 0.277 | 0.098 | 0.044 | 0.001 | 0.182 | 0.015 | 0.018 |
Monthly income (AED), mean ± SD | |||||||||
<10,000 | 46 ± 27.2 | 32.2 ± 25.5 | 43.9 ± 28.1 | 30.3 ± 29.5 | 46.2 ± 32.3 | 37.9 ± 32.6 | 41.7 ± 36 | 31.1 ± 33.3 | 50.8 ± 35.6 |
10,000–20,000 | 37.8 ± 27.3 | 15 ± 25.4 | 40 ± 26.3 | 30 ± 33.1 | 36.7 ± 18.9 | 10 ± 16.1 | 26.7 ± 26.3 | 6.7 ± 14.1 | 20 ± 23.3 |
20,000–30,000 | 42 ± 21.4 | 25.9 ± 22.2 | 33.3 ± 16.7 | 18.5 ± 24.2 | 40.7 ± 27.8 | 33.3 ± 33.3 | 37 ± 35.1 | 7.4 ± 14.7 | 25.9 ± 27.8 |
>30,000 | 23.5 ± 31.2 | 13 ± 33.1 | 22.2 ± 31.2 | 3.7 ± 11.1 | 18.5 ± 33.8 | 14.8 ± 33.8 | 18.5 ± 33.8 | 11.1 ± 33.3 | 11.1 ± 16.7 |
p value | 0.064 | 0.028 | 0.053 | 0.046 | 0.069 | 0.015 | 0.206 | 0.008 | 0.001 |
Physical activity, mean ± SD | |||||||||
Yes | 33.7 ± 25.8 | 20 ± 25.5 | 30 ± 22.1 | 21 ± 26.9 | 31.4 ± 26.7 | 21.9 ± 29.1 | 27.6 ± 30.8 | 11.4 ± 24.2 | 29.5 ± 31.1 |
No | 48.9 ± 27.4 | 32.9 ± 26.8 | 48.2 ± 29.6 | 29.7 ± 30.2 | 49.5 ± 33 | 38.7 ± 33.8 | 44.1 ± 36.9 | 32.4 ± 33.8 | 46.8 ± 36.4 |
p value | 0.018 | 0.026 | 0.005 | 0.209 | 0.015 | 0.022 | 0.053 | 0.001 | 0.036 |
Smoking habits, mean ± SD | |||||||||
Smoker | 41.9 ± 27.3 | 34.6 ± 22 | 34.6 ± 15.9 | 38.5 ± 32.9 | 43.6 ± 31.6 | 35.9 ± 34.6 | 33.3 ± 33.3 | 20.5 ± 29 | 43.6 ± 31.6 |
Nonsmoker | 41.6 ± 28.7 | 24.8 ± 28.3 | 40.6 ± 29.5 | 21.2 ± 27.5 | 40 ± 32.3 | 29.1 ± 33.4 | 37.6 ± 36.3 | 22.4 ± 32.7 | 38.2 ± 36.5 |
Previous smoker | 38.9 ± 11.1 | 25 ± 16.7 | 37.5 ± 34.4 | 41.7 ± 16.7 | 41.7 ± 16.7 | 33.3 ± 0 | 25 ± 16.7 | 25 ± 16.7 | 25 ± 16.7 |
p value | 0.985 | 0.297 | 0.899 | 0.047 | 0.929 | 0.591 | 0.869 | 0.715 | 0.629 |
Children, mean ± SD | |||||||||
Yes | 38.5 ± 27.5 | 27 ± 27 | 38.8 ± 29.4 | 27 ± 28.9 | 37.9 ± 30.2 | 29.3 ± 31.9 | 36.2 ± 36 | 19.5 ± 28.6 | 36.8 ± 34.6 |
No | 54 ± 25 | 25 ± 26.8 | 41.7 ± 19.3 | 19 ± 28.4 | 52.4 ± 33.9 | 35.7 ± 35.7 | 35.7 ± 30.6 | 33.3 ± 39.2 | 45.2 ± 36.1 |
p value | 0.043 | 0.894 | 0.321 | 0.281 | 0.097 | 0.550 | 0.870 | 0.263 | 0.393 |
Stage, mean ± SD | |||||||||
0 | 42 ± 27.1 | 31.5 ± 15.5 | 42.6 ± 23.7 | 25.9 ± 22.2 | 33.3 ± 23.6 | 37 ± 30.9 | 37 ± 30.9 | 18.5 ± 24.2 | 44.4 ± 28.9 |
I | 37.4 ± 24.6 | 21.2 ± 25.3 | 32.6 ± 14.1 | 16.7 ± 22.4 | 33.3 ± 30.9 | 33.3 ± 38.5 | 33.3 ± 34.1 | 15.2 ± 26.7 | 31.8 ± 30 |
II | 42.2 ± 30.3 | 22.2 ± 33.1 | 35.6 ± 27.4 | 15.6 ± 27.8 | 44.4 ± 37.1 | 22.2 ± 30 | 44.4 ± 41.1 | 20 ± 37.4 | 51.1 ± 39.6 |
III | 41.9 ± 28 | 41 ± 27.7 | 51.3 ± 35 | 41 ± 30.9 | 51.3 ± 25.9 | 30.8 ± 31.8 | 35.9 ± 28.7 | 38.5 ± 35.6 | 23.1 ± 31.6 |
IV | 62.2 ± 12.7 | 26.7 ± 25.3 | 53.3 ± 39.8 | 46.7 ± 29.8 | 53.3 ± 38 | 53.3 ± 18.3 | 40 ± 43.5 | 20 ± 18.3 | 66.7 ± 33.3 |
p value | 0.310 | 0.172 | 0.396 | 0.021 | 0.481 | 0.270 | 0.995 | 0.196 | 0.052 |
Radiotherapy, mean ± SD | |||||||||
Yes | 43.6 ± 35 | 21.3 ± 30.6 | 46 ± 35.8 | 12 ± 19 | 44 ± 39.3 | 26.7 ± 38.5 | 34.7 ± 39.1 | 22.7 ± 36.9 | 37.3 ± 43.4 |
No | 40.4 ± 23 | 29.4 ± 24.4 | 35.8 ± 21.7 | 32.6 ± 30.7 | 39 ± 26.3 | 32.6 ± 29.1 | 36.9 ± 32.8 | 22 ± 28 | 39 ± 29.7 |
p value | 0.811 | 0.088 | 0.438 | 0.004 | 0.842 | 0.162 | 0.585 | 0.586 | 0.396 |
Chemotherapy, mean ± SD | |||||||||
Yes | 37.6 ± 28 | 25.2 ± 22.2 | 37.2 ± 28.3 | 28.4 ± 29.5 | 37.6 ± 29.2 | 27.7 ± 29.7 | 33.3 ± 31.1 | 18.4 ± 26.7 | 39.7 ± 34.5 |
No | 48.9 ± 25.7 | 29.3 ± 34.1 | 43.3 ± 26.4 | 20 ± 27.2 | 46.7 ± 34.7 | 36 ± 37.2 | 41.3 ± 41.1 | 29.3 ± 37.7 | 36 ± 35.9 |
p value | 0.096 | 0.966 | 0.272 | 0.212 | 0.241 | 0.439 | 0.568 | 0.316 | 0.600 |
Metastasis, mean ± SD | |||||||||
Yes | 51.5 ± 31.9 | 38.6 ± 29.3 | 48.5 ± 34.5 | 28.8 ± 25.8 | 50 ± 32.1 | 47 ± 33.6 | 45.5 ± 33.4 | 19.7 ± 26.5 | 45.5 ± 35 |
No | 35.3 ± 23.7 | 17.5 ± 21.3 | 34.2 ± 22.3 | 20.8 ± 28.9 | 35.8 ± 31.5 | 20.8 ± 30.8 | 30 ± 35.2 | 20 ± 32.7 | 37.5 ± 36.3 |
p value | 0.037 | 0.004 | 0.191 | 0.146 | 0.119 | 0.002 | 0.057 | 0.623 | 0.325 |
Characteristics | Symptom Experience b | Body Image b | Sexual/Vaginal Functioning (n = 44) b | Lymphedema b | Peripheral Neuropathy b | Menopausal Symptoms b | Sexual Worry b |
---|---|---|---|---|---|---|---|
Age (years), mean ± SD | |||||||
24–34 | 36.6 ± 17.8 | 39.3 ± 21.4 | 28.3 ± 21.6 | 22.2 ± 30 | 24.4 ± 29.5 | 26.7 ± 28.7 | 28.9 ± 30.5 |
35–44 | 24.9 ± 16.7 | 39.8 ± 31.0 | 41.2 ± 31.4 | 12.9 ± 18.6 | 23.7 ± 26.1 | 35.5 ± 24.2 | 43 ± 31.3 |
45–54 | 32.8 ± 16.3 | 42.6 ± 35.7 | 29.8 ± 20.4 | 52.8 ± 33.2 | 50 ± 26.6 | 47.2 ± 33.2 | 36.1 ± 38.8 |
54–72 | 29.7 ± 17.6 | 34.9 ± 38.9 | 3.10 ± 8.8 | 33.3 ± 43.4 | 31 ± 38 | 23.8 ± 27.5 | 7.1 ± 19.3 |
p value | 0.176 | 0.837 | 0.005 | 0.007 | 0.049 | 0.124 | 0.003 |
Time since diagnosis (years), mean ± SD | |||||||
<1 | 35.3 ± 15.4 | 34.5 ± 25.4 | 30.9 ± 27.4 | 31.6 ± 30.4 | 26.3 ± 28.5 | 40.4 ± 30.6 | 38.6 ± 33.8 |
1–2 | 27.9 ± 15.3 | 38.1 ± 31.6 | 27.7 ± 28.4 | 21.9 ± 31.3 | 32.4 ± 30.8 | 31.4 ± 24.2 | 26.7 ± 34.1 |
2–3 | 24.9 ± 21.9 | 51.9 ± 41.2 | 37.5 ± 34.3 | 25.9 ± 40.1 | 37 ± 35.1 | 37 ± 38.9 | 37 ± 30.9 |
3–4 | 38.4 ± 34.5 | 40.7 ± 28.0 | 25.0 ± – | 33.3 ± 33.3 | 33.3 ± 33.3 | 22.2 ± 38.5 | 55.6 ± 19.2 |
4–5 | 24.2 ± 18.4 | 55.6 ± 38.5 | 11.1 ± 19.2 | 0 ± 0 | 33.3 ± 0 | 11.1 ± 19.2 | |
>5 | 24.2 ± 21.2 | 25.9 ± 35.7 | 33.3 ± 57.7 | 22.2 ± 38.5 | 11.1 ± 19.2 | 38.6 ± 33.8 | |
p value | 0.550 | 0.803 | 0.898 | 0.752 | 0.425 | 0.541 | 0.291 |
Marital status, mean ± SD | |||||||
Single | 38.5 ± 19.7 | 53.3 ± 31.8 | 38.9 ± 38.6 | 29.2 ± 9.2 | 33.3 ± 41.6 | 30 ± 33.1 | 23.3 ± 38.7 |
Married | 28.7 ± 16.2 | 36.6 ± 31.0 | 29.4 ± 27.5 | 33.8 ± 4.6 | 30.9 ± 29.3 | 34.5 ± 28.7 | 36.4 ± 32.2 |
Divorced | 23.8 ± 20.7 | 39.7 ± 31.3 | 16.6 ± 20.4 | 26.2 ± 9.9 | 14.3 ± 17.8 | 28.6 ± 12.6 | 9.5 ± 16.3 |
p value | 0.287 | 0.279 | 0.563 | 0.511 | 0.394 | 0.789 | 0.046 |
Education level, mean ± SD | |||||||
Illiterate | 35.4 ± 17.8 | 40.7 ± 52.5 | 41.6 ± – | 55.6 ± 50.9 | 44.4 ± 38.5 | 44.4 ± 50.9 | 33.3 ± 57.7 |
Primary and preparatory school | 37.1 ± 15.3 | 42.6 ± 40.2 | 20.8 ± 29.9 | 30.6 ± 46 | 41.7 ± 32.2 | 44.4 ± 29.6 | 11.1 ± 29.6 |
Secondary school | 28.1 ± 18.9 | 30.9 ± 22.4 | 30.8 ± 24.5 | 35.2 ± 31.3 | 25.9 ± 33.4 | 31.5 ± 31.3 | 27.8 ± 34.8 |
University undergraduate | 27.7 ± 14.7 | 44.1 ± 29.8 | 38.8 ± 29.0 | 14.9 ± 22.9 | 25.3 ± 26.2 | 32.2 ± 22.7 | 41.4 ± 29.1 |
University graduate | 27.0 ± 23.5 | 35.6 ± 34.3 | 8.3 ± 11.8 | 23.3 ± 27.4 | 30 ± 33.1 | 23.3 ± 27.4 | 36.7 ± 29.2 |
p value | 0.313 | 0.789 | 0.068 | 0.162 | 0.447 | 0.425 | 0.023 |
Employment, mean ± SD | |||||||
Yes | 26.5 ± 17.4 | 40.9 ± 30.4 | 37.3 ± 32.1 | 17.9 ± 24.8 | 28.5 ± 30.3 | 29.3 ± 20 | 38.2 ± 33 |
No | 33.6 ± 16.7 | 36.9 ± 32.8 | 22.4 ± 21.3 | 35.5 ± 38.4 | 31.2 ± 31 | 38.7 ± 35.6 | 23.7 ± 31.3 |
p value | 0.046 | 0.537 | 0.130 | 0.056 | 0.684 | 0.420 | 0.042 |
Monthly income (AED), mean ± SD | |||||||
<10,000 | 34.2 ± 17.5 | 45.5 ± 33.4 | 28.6 ± 27.5 | 34.1 ± 33.3 | 32.1 ± 4.8 | 34.8 ± 31.3 | 29.5 ± 34.6 |
10,000–20,000 | 23.9 ± 13.2 | 31.1 ± 22.1 | 58.3 ± 26.3 | 10 ± 22.5 | 30.6 ± 9.7 | 40 ± 21.1 | 50 ± 28.3 |
20,000–30,000 | 28.6 ± 11.6 | 38.3 ± 28.9 | 22.9 ± 15.7 | 18.5 ± 33.8 | 24.2 ± 8.1 | 33.3 ± 23.6 | 29.6 ± 35.1 |
>30,000 | 14.5 ± 16.9 | 18.5 ± 22.9 | 0 ± 0 | 7.4 ± 22.2 | 24.2 ± 8.1 | 18.5 ± 17.6 | 25.9 ± 22.2 |
p value | 0.011 | 0.087 | 0.071 | 0.015 | 0.280 | 0.283 | 0.212 |
Physical activity, mean ± SD | |||||||
Yes | 22.6 ± 14.8 | 35.2 ± 26.6 | 28.9 ± 29.5 | 14.3 ± 21.8 | 18.1 ± 21.9 | 25.7 ± 19.9 | 32.4 ± 32.8 |
No | 36.2 ± 17.1 | 42.9 ± 35.1 | 29.9 ± 27.1 | 36 ± 37.2 | 40.5 ± 33.5 | 40.5 ± 32.5 | 31.5 ± 33.3 |
p value | < 0.001 | 0.417 | 0.769 | 0.011 | 0.003 | 0.056 | 0.881 |
Smoking habits, mean ± SD | |||||||
Smoker | 34.7 ± 14.1 | 47.9 ± 28.1 | 36.1 ± 24.7 | 12.8 ± 21.7 | 25.6 ± 24.2 | 33.3 ± 19.2 | 56.4 ± 34.4 |
Nonsmoker | 28.3 ± 18.1 | 38.4 ± 32.6 | 28.0 ± 29.2 | 29.1 ± 34.6 | 31.5 ± 32.3 | 32.7 ± 29 | 26.1 ± 31.2 |
Previous smoker | 31.1 ± 16.3 | 22.2 ± 12.8 | 25.0 ± 23.6 | 16.7 ± 19.2 | 16.7 ± 19.2 | 41.7 ± 41.9 | 33.3 ± 0 |
p value | 0.501 | 0.328 | 0.521 | 0.310 | 0.686 | 0.873 | 0.012 |
Children, mean ± SD | |||||||
Yes | 27.8 ± 15.9 | 37.5 ± 31.5 | 27.4 ± 25.3 | 26.4 ± 33.5 | 29.9 ± 30.4 | 33.3 ± 26.5 | 33.9 ± 32.7 |
No | 37.0 ± 21.3 | 46.0 ± 30.5 | 38.0 ± 36.4 | 21.4 ± 28.1 | 28.6 ± 31.6 | 33.3 ± 34.6 | 23.8 ± 33.1 |
p value | 0.121 | 0.288 | 0.565 | 0.707 | 0.855 | 0.733 | 0.237 |
Stage, mean ± SD | |||||||
0 | 39.7 ± 17.8 | 30.9 ± 31.8 | 22.9 ± 17.1 | 40.7 ± 36.4 | 40.7 ± 32.4 | 48.1 ± 37.7 | 22.2 ± 33.3 |
I | 26.9 ± 16.7 | 43.4 ± 28.9 | 44.4 ± 28.9 | 18.2 ± 33.7 | 25.8 ± 25.1 | 31.8 ± 24.1 | 37.9 ± 33 |
II | 23.8 ± 14.6 | 45.9 ± 34.9 | 53.3 ± 36.6 | 13.3 ± 21.1 | 11.1 ± 16.3 | 28.9 ± 27.8 | 33.3 ± 35.6 |
III | 35.4 ± 15.8 | 35.0 ± 22.2 | 25 ± 26.4 | 28.2 ± 32.9 | 41 ± 30.9 | 38.5 ± 18.5 | 38.5 ± 35.6 |
IV | 37.0 ± 23.2 | 51.1 ± 47.5 | 21.7 ± 26.7 | 40 ± 27.9 | 40 ± 54.8 | 26.7 ± 43.5 | 33.3 ± 23.6 |
p value | 0.106 | 0.724 | 0.245 | 0.104 | 0.056 | 0.354 | 0.708 |
Radiotherapy, mean ± SD | |||||||
Yes | 25.1 ± 19.0 | 42.7 ± 38.0 | 26.8 ± 34.3 | 17.3 ± 33.5 | 32 ± 35.3 | 30.7 ± 30.3 | 29.3 ± 36.4 |
No | 32.0 ± 16.1 | 37.4 ± 27.3 | 30.8 ± 24.7 | 29.8 ± 31.3 | 28.4 ± 27.8 | 34.8 ± 26.9 | 33.3 ± 31.1 |
p value | 0.111 | 0.796 | 0.266 | 0.037 | 0.885 | 0.427 | 0.416 |
Chemotherapy, mean ± SD | |||||||
Yes | 28.2 ± 17.0 | 40.7 ± 31.6 | 29.2 ± 27.9 | 27.7 ± 31.3 | 31.9 ± 31.8 | 28.4 ± 23 | 38.3 ± 33.3 |
No | 32.2 ± 18.0 | 36.4 ± 31.0 | 30.1 ± 28.3 | 21.3 ± 34.5 | 25.3 ± 27.7 | 42.7 ± 34 | 20 ± 28.9 |
p value | 0.235 | 0.513 | 0.884 | 0.234 | 0.438 | 0.086 | 0.017 |
Metastasis, mean ± SD | |||||||
Yes | 33.9 ± 17.2 | 47.0 ± 35.0 | 12.5 ± 23.4 | 33.3 ± 37.1 | 36.4 ± 35.5 | 34.8 ± 26.2 | 33.3 ± 32.5 |
No | 24.6 ± 15.5 | 36.1 ± 31.3 | 29.9 ± 30.2 | 16.7 ± 28.2 | 24.2 ± 26.1 | 30 ± 27 | 32.5 ± 35.8 |
p value | 0.044 | 0.259 | 0.101 | 0.037 | 0.216 | 0.425 | 0.791 |
Characteristic | Sexual Activity b (n = 72) | Sexual Enjoyment b (n = 47) |
---|---|---|
Age (years), mean ± SD | ||
24–34 | 33.3 ± 33.3 | 26.7 ± 30.6 |
35–44 | 33.3 ± 24.3 | 28.3 ± 29.2 |
45–54 | 22.2 ± 25.9 | 40.7 ± 27.8 |
54–72 | 9.5 ± 20.4 | 12.5 ± 35.4 |
p value | 0.023 | 0.143 |
Time since diagnosis (years), mean ± SD | ||
<1 | 29.8 ± 29.2 | 33.3 ± 32.2 |
1–2 | 21.9 ± 25.5 | 25.6 ± 31.7 |
2–3 | 22.2 ± 23.6 | 16.7 ± 19.2 |
3–4 | 66.7 ± 0 | 33.3 ± 32.2 |
4–5 | 33.3 ± 33.3 | – |
>5 | 33.3 ± 33.3 | – |
p value | 0.169 | 0.739 |
Marital status, mean ± SD | ||
Single | 23.3 ± 38.7 | 27.8 ± 32.8 |
Married | 29.1 ± 24.9 | 25.9 ± 28.9 |
Divorced | 14.3 ± 26.2 | 40 ± 43.5 |
p value | 0.208 | 0.776 |
Education level, mean ± SD | ||
Illiterate | 0 ± 0 | 0 ± 0 |
Primary and preparatory school | 8.3 ± 15.1 | 8.3 ± 15.1 |
Secondary school | 25.9 ± 29.3 | 25.9 ± 29.3 |
University undergraduate | 34.5 ± 25.9 | 34.5 ± 25.9 |
University graduate | 36.7 ± 29.2 | 36.7 ± 29.2 |
p value | 0.010 | 0.496 |
Employment, mean ± SD | ||
Yes | 33.3 ± 25.8 | 21.2 ± 24.2 |
No | 18.3 ± 27 | 33.3 ± 34.7 |
p value | 0.010 | 0.272 |
Monthly income (AED), mean ± SD | ||
<10,000 | 21.2 ± 27 | 28.7 ± 32 |
10,000–20,000 | 43.3 ± 22.5 | 41.7 ± 31.9 |
20,000–30,000 | 29.6 ± 26.1 | 20 ± 18.3 |
>30,000 | 33.3 ± 28.9 | 0 ± 0 |
p value | 0.066 | 0.384 |
Physical activity, mean ± SD | ||
Yes | 28.6 ± 25.7 | 22.8 ± 29.5 |
No | 25.2 ± 28.8 | 31 ± 31.3 |
p value | 0.480 | 0.358 |
Smoking habits, mean ± SD | ||
Smoker | 41 ± 14.6 | 23.3 ± 22.5 |
Nonsmoker | 23.6 ± 29.2 | 30.4 ± 33.2 |
Previous smoker | 25 ± 16.7 | 11.1 ± 19.2 |
p value | 0.044 | 0.604 |
Children, mean ± SD | ||
Yes | 28.2 ± 26.3 | 28.1 ± 30.5 |
No | 21.4 ± 31 | 25.9 ± 32.4 |
p value | 0.279 | 0.816 |
Stage, mean ± SD | ||
0 | 22.2 ± 33.3 | 37.5 ± 27.8 |
I | 33.3 ± 23 | 24.2 ± 21.6 |
II | 22.2 ± 27.2 | 33.3 ± 42.2 |
III | 33.3 ± 30.4 | 18.5 ± 29.4 |
IV | 26.7 ± 27.9 | 33.3 ± 33.3 |
p value | 0.519 | 0.659 |
Radiotherapy, mean ± SD | ||
Yes | 17.3 ± 23.8 | 14.3 ± 31.3 |
No | 31.9 ± 27.8 | 33.3 ± 28.9 |
p value | 0.029 | 0.019 |
Chemotherapy, mean ± SD | ||
Yes | 30.5 ± 25.8 | 33.3 ± 30.9 |
No | 20 ± 28.9 | 18.5 ± 28.5 |
p value | 0.067 | 0.082 |
Metastasis, mean ± SD | ||
Yes | 30.3 ± 27 | 29.2 ± 27.8 |
No | 21.7 ± 24.5 | 23.3 ± 31.7 |
p value | 0.215 | 0.456 |
Variable | β | p Value |
---|---|---|
Intercept | 90.876 | <0.001 |
Marital status | −0.053 | 0.656 |
Education level | 0.153 | 0.268 |
Employment | 0.142 | 0.316 |
Income (AED) | 0.502 | <0.001 |
Cancer stage | 0.158 | 0.180 |
Time since diagnosis (years) | −0.137 | 0.257 |
Radiotherapy | −0.133 | 0.272 |
Chemotherapy | −0.055 | 0.624 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Smail, L. Quality of Life of Emirati Women with Cervical Cancer Using EORTC QLQ-30 and CX24: A First Look in the UAE. Int. J. Environ. Res. Public Health 2025, 22, 671. https://doi.org/10.3390/ijerph22050671
Smail L. Quality of Life of Emirati Women with Cervical Cancer Using EORTC QLQ-30 and CX24: A First Look in the UAE. International Journal of Environmental Research and Public Health. 2025; 22(5):671. https://doi.org/10.3390/ijerph22050671
Chicago/Turabian StyleSmail, Linda. 2025. "Quality of Life of Emirati Women with Cervical Cancer Using EORTC QLQ-30 and CX24: A First Look in the UAE" International Journal of Environmental Research and Public Health 22, no. 5: 671. https://doi.org/10.3390/ijerph22050671
APA StyleSmail, L. (2025). Quality of Life of Emirati Women with Cervical Cancer Using EORTC QLQ-30 and CX24: A First Look in the UAE. International Journal of Environmental Research and Public Health, 22(5), 671. https://doi.org/10.3390/ijerph22050671